Opinion|Videos|January 31, 2025
Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors
Panelists discuss how they collaborate with community sites for chimeric antigen receptor (CAR) T and bispecifics administration, accessibility, and monitoring, and explore the factors influencing the use of tazemetostat or zanubrutinib + obinutuzumab, including patient selection, accessibility, and sequencing in relation to CAR T or bispecific therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you partner or collaborate with community sites regarding CAR T and bispecifics administration, accessibility, and monitoring?
- Which patients do you consider tazemetostat or zanubrutinib + obinutuzumab for, and how does accessibility of these agents factor? How are you sequencing these agents in relationship to CAR T or the bispecifics?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5